000			04187nam a2200421 i 4500
999			_c112673 _d112673
001			112673
003			ES-MaUEC
005			20230217113158.0
006			a||||fo|||| 00| 0
007			cr nn 008mamaa
008			181016s2019 gw a o |||| 0|eng d
020			_a9783319993508
024	7		_a10.1007/978-3-319-99350-8 _2doi
040			_bspa _cES-MaUEC _dES-MaUEC
050		4	_aRC280.B8 _b2019 EB
245	0	0	_aEstrogen Receptor and Breast Cancer : _bCelebrating the 60th Anniversary of the Discovery of ER _cedited by Xiaoting Zhang
264		1	_aCham _bSpringer International Publishing _c2019
300			_a1 recurso en línea (XII, 417 páginas) _b79 ilustraciones, 69 ilustraciones a color
336			_2rdacontent _aTexto _btxt
337			_2rdamedia _aelectrónico _bc
338			_2rdacarrier _arecurso electrónico _bcr
347			_atext file _bPDF
490	0		_aCancer Drug Discovery and Development _x2196-9906
490	0		_aMedicine (Springer-11650)
505	0		_a1. Introduction: On the discovery of Estrogen Receptor -- 2. Physiological and Pathological Roles of Estrogen Receptor -- 3. Estrogen Receptor Cofactors -- 4. ER-Mediated Gene Transcription -- 5. ER Transcriptome -- 6. Estrogen Receptor Regulation of Non-Coding RNAs in Breast Cancer -- 7. First Targeted Therapy --- History of Tamoxifen -- 8. Selective Estrogen Receptor Modulators (SERMs) -- 9. New Estrogen Receptor Drugs -- 10. Endocrine Therapy in Clinical Practice -- 11. Structural Insights into ER and Anti-Estrogen Therapies -- 12. Molecular Mechanisms of Endocrine Resistance -- 13. Estrogen Receptor Mutants in Breast Cancer -- 14. Estrogen Receptor Beta and Isoforms in Breast Cancer -- 15. Xenoestrogens, Phytoestrogens and Breast Cancer -- 16. Emerging Approaches to Overcome Endocrine Resistance.
520	3		_aThe discovery of ER by Dr. Elwood Jensen exactly 60 years ago has not only led to the birth of a whole new vital nuclear receptor research field but also made a rapid, direct and lasting impact on the treatment and prevention of breast cancer. Since that landmark discovery, tremendous progress has been made in our understanding of the molecular functions of ER and development of targeted therapies against ER pathways for breast cancer treatment. However, there is currently no book available addressing these discoveries and recent advancement in a historical and systematic fashion. This book is intended to provide comprehensive, most up-to-date information on the history and recent advancement of ER and breast cancer by world renowned leaders in the field. These chapters include the history of the discovery of ER; physiological and pathological roles of ER; recent discovery of ER cistrome, transcriptome and its regulation of noncoding RNAs such as microRNAs and enhancer RNAs in breast cancer; development and clinical practices of the first targeted therapy Tamoxifen and other antiestrogens for breast cancer treatment; structural basis of ER and antiestrogen actions; molecular insights into endocrine resistance; the role of ER mutants, ER-beta and environmental estrogens in breast cancer; and emerging state-of-the-art therapeutic approaches currently in development to overcome treatment resistance and future perspectives. The book will provide undergraduate and graduate students, basic scientists and clinical cancer researchers, residents, fellows, as well as clinicians, oncology educators and the general public a thorough and authoritative review of these exciting topics.
988			_aSpringer_Medicine_2019
650		7	_aMamas _2embne _9182522 _xCáncer
650		7	_aHormonas sexuales _2embne _9675054
700	1		_aZhang, Xiaoting. _eeditor literario _4edt _4http://id.loc.gov/vocabulary/relators/edt
710	2		_aSpringerLink (Online service) _9106996
776	0	8	_iPrinted edition: _z9783319993492
776	0	8	_iPrinted edition: _z9783319993515
776	0	8	_iPrinted edition: _z9783030075934
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://doi.org/10.1007/978-3-319-99350-8 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
942			_2lcc _cLE
998			_dz _b02/2023 _eb _zSI